South Korea’s Daewoong Pharmaceutical Co. has obtained a patent for the use of its botulinum toxin Nabota in the treatment of migraines in the U.S. The patent is expected to bolster the company’s plans to enter the therapeutic market in addition to the cosmetics market, which it had aimed for since the early stages of Nabota development.

Daewoong Pharmaceutical announced on Thursday that it has received a patent right from the U.S. Patent and Trademark Office (USPTO) for its self-developed botulinum toxin ABP-450, marketed as Nabota, as a “neurotoxin composition for the treatment of migraines.”

The patent application was led by AEON Biopharma, Daewoong Pharmaceutical’s U.S. partner.

AEON Biopharma demonstrated that the botulinum toxin product offers advantages such as reduced dosing frequency and improved ease of use through changes in administration location compared to existing botulinum toxin products.

The product was also acknowledged for its ability to reduce side effects. This patent provides market exclusivity for ABP-450 in the U.S. until 2041.

Daewoong Pharmaceutical plans to expand the therapeutic indications of Nabota to include conditions such as episodic (intermittent) and chronic migraines, cervical dystonia, and gastroparesis in the U.S.

By Kim Jee-hee and Minu Kim

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]